新生儿早发败血症抗生素治疗的研究进展

Progress of Antibiotic Treatment of Early-onset Sepsis in Neonates

新生儿早发败血症(EOS)是指患儿在出生72h内出现因真菌活细菌感染引起的全身炎性反应综合征,其发病机制与新生儿晚发败血症(LOS)一致。LOS多见于早产儿,EOS则多见于足月儿,两症均具有起病突然、发展迅速和致命性强的特点,治疗也均以抗生素为主。但近些年来广谱抗生素被滥用,EOS相关病原体不断发生变化,对于多种抗生素出现不同的耐药性,导致诊治难度提升,因此选用恰当的抗生素直接影响患儿的疗效和预后。因此该文就近年来EOS的治疗情况、抗生素应用及耐药性情况等进行综述。

Early-onset sepsis of the newborn(EOS)is a syndrome of systemic inflammatory reaction caused by fungal live bacterial infection that occurs within 72 h of birth,and its pathogenesis is consistent with late-onset sepsis of the newborn(LOS).The pathogenesis is consistent with late-onset sepsis of the newborn(LOS).LOS is more common in preterm infants,while EOS is more common in term infants,and both syndromes are characterized by sudden onset,rapid development,and high lethality,and the treatment is mainly based on antibiotics.However,in recent years,broad-spectrum antibiotics have been abused,and the pathogens associated with EOS have been changing,showing different resistance to multiple antibiotics,which makes the diagnosis and treatment more difficult,so the selection of appropriate antibiotics has a direct impact on the efficacy and prognosis of the children.Therefore,this article reviews the treatment of EOS,antibiotic application and drug resistance in recent years.